Cipla has entered into a partnership with Eli Lilly and Co (India) Pvt. Ltd., a 100 per cent subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader, for the marketing and distribution of Lilly’s Basaglar (insulin glargine injection) in India.

Under this agreement, Lilly’s Basaglar will be marketed and distributed in India by Cipla. It expects to start commercialising Basaglar in India by end of the year 2018.

Diabetes continues to be a focus area for Cipla and with the launch of strong brand like Basaglar, Cipla will be at the forefront of providing a holistic diabetes care with the most comprehensive portfolio across orals and injectables. Cipla’s focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatment and medication.

According to Eli Lilly, this strategic partnership leverages the company’s commitment to bring innovation to people suffering from diabetes in India and Cipla’s strong on-ground footprint across the country.